Arcus Biosciences, Inc. (RCUS) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-13

Arcus Biosciences, Inc. (RCUS) has filed 13 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-13. 3 Form 8-K material event filings were reported by RCUS in the last 90 days. 7 Form 144 notices of proposed sale were filed for RCUS stock. InsiderAlpha tracks every RCUS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Arcus Biosciences, Inc. (RCUS)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001724521

90-Day SEC Filing Activity

Form 4 filings (90d)	13
Form 8-K filings (90d)	3
Form 144 notices (90d)	7
Latest Form 4 filing	2026-07-13

Recent RCUS Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-07-10	Jaen Juan C.	President	S — Open-market sale [10b5-1]	19.8K	$28.61	$566K	SEC
2026-07-10	Jaen Juan C.	President	S — Open-market sale [10b5-1]	268	$29.40	$8K	SEC
2026-07-09	Jaen Juan C.	President	S — Open-market sale [10b5-1]	48.5K	$30.05	$1.46M	SEC
2026-06-24	Jaen Juan C.	President	S — Open-market sale	6.4K	$29.66	$191K	SEC
2026-06-23	Jaen Juan C.	President	S — Open-market sale	14.1K	$27.69	$389K	SEC
2026-06-23	Jaen Juan C.	President	S — Open-market sale	1.7K	$28.06	$48K	SEC
2026-06-22	Jaen Juan C.	President	S — Open-market sale	9.2K	$27.03	$250K	SEC
2026-06-11	Tang Carolyn C.	General Counsel	M — Option exercise	34.1K	$2.57	$88K	SEC
2026-06-11	Lacey David L.	Director	A — Grant or award	5.7K	$0.00	—	SEC
2026-06-11	Ribas Antoni	Director	A — Grant or award	5.7K	$0.00	—	SEC
2026-06-11	Machado Patrick	Director	A — Grant or award	5.7K	$0.00	—	SEC
2026-06-11	KANEKO YASUNORI	Director	A — Grant or award	5.7K	$0.00	—	SEC
2026-06-11	FALBERG KATHRYN E	Director	A — Grant or award	5.7K	$0.00	—	SEC
2026-06-11	Lambert Nicole	Director	A — Grant or award	5.7K	$0.00	—	SEC
2026-06-11	PERLMAN ANDREW J	Director	A — Grant or award	5.7K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Arcus Biosciences, Inc. (RCUS). Updated in real time as new filings are submitted to the SEC.

Most-Active RCUS Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Jaen Juan C.	7	$2.91M
Ribas Antoni	3	—
PERLMAN ANDREW J	2	—
KANEKO YASUNORI	2	—
FALBERG KATHRYN E	2	—

Recent RCUS Form 8-K Material Events

2026-06-12 — Item 5.07 [SEC]
2026-05-05 — Item 2.02, 9.01 [SEC]
2026-04-20 — Item 8.01 · Clinical · negative [SEC]
Arcus Biosciences announced discontinuation of the Phase 3 STAR-121 study evaluating domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer due to futility based on an Independent Data Monitoring Committee
2026-03-23 — Item 5.02 · Leadership · neutral [SEC]
Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, resigned effective March 30, 2026. The resignation was not due to any disagreement with the company, and Jarrett will provide advisory services through June 30, 2026 in exchange for an extended option exercise period
2026-02-25 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Arcus Biosciences issued a press release on February 25, 2026 announcing its financial results for Q4 2025 and full year 2025. This is a routine quarterly earnings disclosure with no indication of material surprises, strategic changes, or clinical developments mentioned in the 8-

Recent RCUS Form 144 Notices of Proposed Sale

2026-07-09 — — [SEC]
2026-06-24 — — [SEC]
2026-06-22 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-07-13 — Jaen Juan C. (President)
2026-06-24 — Jaen Juan C. (President)
2026-06-12 — Lambert Nicole (Director)
2026-06-12 — Machado Patrick (Director)
2026-06-12 — KANEKO YASUNORI (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RCUS insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

RCUS Insider Trading — FAQ

What is the latest insider trade for RCUS?: Arcus Biosciences, Inc. (RCUS) had 13 insider filings in the last 90 days, with the most recent on 2026-07-13. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying RCUS stock?: 0 insider purchases of RCUS were filed in the last 90 days.
How many insiders are selling RCUS stock?: 0 insider sales of RCUS were filed in the last 90 days.
Where can I see RCUS SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every RCUS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live RCUS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.